LPCN – lipocine inc. (US:NASDAQ)
Stock Stats
News
Lipocine (NASDAQ:LPCN) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) [Yahoo! Finance]
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine (NASDAQ:LPCN) had its price target lowered by analysts at HC Wainwright from $8.00 to $7.00. They now have a "buy" rating on the stock.
Lipocine (NASDAQ:LPCN) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Form 8-K Lipocine Inc. For: Nov 18
Form 8-K Lipocine Inc. For: Nov 18
Form 8-K Lipocine Inc. For: Nov 06
Form 10-Q Lipocine Inc. For: Sep 30
Form 8-K Lipocine Inc. For: Nov 04
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.